Connect with us

Company News

Inspira™ Technologies closes $3.88M registered direct offering

Inspira Technologies OXY BHN Ltd. announces the closing of its previously announced registered direct offering of 3,031,250 ordinary shares (or ordinary share equivalents in lieu thereof), at a purchase price of $1.28 per ordinary share (or ordinary share equivalents in lieu thereof). Inspira has also issued in a private placement warrants to purchase up to an aggregate of 3,031,250 ordinary shares at an exercise price of $1.28 per share. The warrants are exercisable immediately upon issuance on the closing date and will expire on the date that is three and one-half half year after the closing date. The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The securities described above (excluding the unregistered warrants and the ordinary shares underlying the unregistered warrants) were offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form F-3 (Registration No. 333-266748), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 10, 2022 and declared effective by the SEC on August 18, 2022. The offering of such securities in the registered direct offering were made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and accompanying base prospectus may also be obtained, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].

The unregistered warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the ordinary shares underlying such warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and the underlying ordinary shares may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
MB Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!